Advances in locally administered nucleic acid therapeutics.

Bioact Mater · 2025 · PMC11938090 · PMID 40144794

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Phase I/II clinical data showed that ARCT-032 did not cause any adverse effects in the participants and showed a trend toward improved lung function after two doses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.